Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 30 entries
Sorted by: Best Match Show Resources per page
Detection of phosphorylated Akt and MAPK in cell culture assays.

MethodsX

Molgaard S, Ulrichsen M, Olsen D, Glerup S.
PMID: 27274457
MethodsX. 2016 Apr 29;3:386-98. doi: 10.1016/j.mex.2016.04.009. eCollection 2016.

This article describes an immunocytochemistry (ICC) method for staining against phosphorylated forms of the kinases Akt (pAkt) and MAPK (pMAPK). Phosphorylation is induced upon their activation by a number stimuli including insulin and brain-derived neurotrophic factor (BDNF), and is...

Cite
Molgaard S, Ulrichsen M, Olsen D, et al. Detection of phosphorylated Akt and MAPK in cell culture assays. MethodsX. 2016;3:386-98doi: 10.1016/j.mex.2016.04.009.
Molgaard, S., Ulrichsen, M., Olsen, D., & Glerup, S. (2016). Detection of phosphorylated Akt and MAPK in cell culture assays. MethodsX, 3386-98. https://doi.org/10.1016/j.mex.2016.04.009
Molgaard, Simon, et al. "Detection of phosphorylated Akt and MAPK in cell culture assays." MethodsX vol. 3 (2016): 386-98. doi: https://doi.org/10.1016/j.mex.2016.04.009
Molgaard S, Ulrichsen M, Olsen D, Glerup S. Detection of phosphorylated Akt and MAPK in cell culture assays. MethodsX. 2016 Apr 29;3:386-98. doi: 10.1016/j.mex.2016.04.009. eCollection 2016. PMID: 27274457; PMCID: PMC4885140.
Copy Download .nbib Format: NLM
Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication.

Drugs - real world outcomes

Cid Ruzafa J, Ulrichsen SP, Bennett D, Ehrenstein V.
PMID: 31376066
Drugs Real World Outcomes. 2019 Sep;6(3):133-140. doi: 10.1007/s40801-019-0160-6.

INTRODUCTION: A Direct Healthcare Professional Communication (DHPC) sent in Denmark on 11 August 2011 provided information on new pioglitazone labelling and guidance on monitoring treatment effectiveness. We describe pioglitazone use in Denmark after the DHPC, estimate the incidence of...

Cite
Cid Ruzafa J, Ulrichsen SP, Bennett D, et al. Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication. Drugs Real World Outcomes. 2019;6(3):133-140doi: 10.1007/s40801-019-0160-6.
Cid Ruzafa, J., Ulrichsen, S. P., Bennett, D., & Ehrenstein, V. (2019). Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication. Drugs - real world outcomes, 6(3), 133-140. https://doi.org/10.1007/s40801-019-0160-6
Cid Ruzafa, Javier, et al. "Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication." Drugs - real world outcomes vol. 6,3 (2019): 133-140. doi: https://doi.org/10.1007/s40801-019-0160-6
Cid Ruzafa J, Ulrichsen SP, Bennett D, Ehrenstein V. Post-authorisation Safety Study of Pioglitazone Use and Safety Endpoints of Interest in Denmark After Direct Healthcare Professional Communication. Drugs Real World Outcomes. 2019 Sep;6(3):133-140. doi: 10.1007/s40801-019-0160-6. PMID: 31376066; PMCID: PMC6702533.
Copy Download .nbib Format: NLM
Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma.

Cureus

Pandya SK, Ulrickson M, Dong J, Willen R, Pandya A.
PMID: 34178496
Cureus. 2021 May 22;13(5):e15174. doi: 10.7759/cureus.15174.

Seronegative myasthenia gravis is a rare, but potential adverse effect of immune checkpoint inhibition. There have been few but increasing number of cases reported in recent years, and early recognition is important for prompt diagnosis and management. Here, we...

Cite
Pandya SK, Ulrickson M, Dong J, et al. Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma. Cureus. 2021;13(5):e15174doi: 10.7759/cureus.15174.
Pandya, S. K., Ulrickson, M., Dong, J., Willen, R., & Pandya, A. (2021). Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma. Cureus, 13(5), e15174. https://doi.org/10.7759/cureus.15174
Pandya, Shaunak K, et al. "Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma." Cureus vol. 13,5 (2021): e15174. doi: https://doi.org/10.7759/cureus.15174
Pandya SK, Ulrickson M, Dong J, Willen R, Pandya A. Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma. Cureus. 2021 May 22;13(5):e15174. doi: 10.7759/cureus.15174. PMID: 34178496; PMCID: PMC8216640.
Copy Download .nbib Format: NLM
Affective lability as a prospective predictor of subsequent bipolar disorder diagnosis: a systematic review.

International journal of bipolar disorders

Taylor RH, Ulrichsen A, Young AH, Strawbridge R.
PMID: 34719775
Int J Bipolar Disord. 2021 Nov 01;9(1):33. doi: 10.1186/s40345-021-00237-1.

OBJECTIVES: The early pathogenesis and precursors of Bipolar Disorder (BD) are poorly understood. There is some cross-sectional and retrospective evidence of affective lability as a predictor of BD, but this is subject to recall biases. The present review synthesises...

Cite
Taylor RH, Ulrichsen A, Young AH, et al. Affective lability as a prospective predictor of subsequent bipolar disorder diagnosis: a systematic review. Int J Bipolar Disord. 2021;9(1):33doi: 10.1186/s40345-021-00237-1.
Taylor, R. H., Ulrichsen, A., Young, A. H., & Strawbridge, R. (2021). Affective lability as a prospective predictor of subsequent bipolar disorder diagnosis: a systematic review. International journal of bipolar disorders, 9(1), 33. https://doi.org/10.1186/s40345-021-00237-1
Taylor, Rosie H, et al. "Affective lability as a prospective predictor of subsequent bipolar disorder diagnosis: a systematic review." International journal of bipolar disorders vol. 9,1 (2021): 33. doi: https://doi.org/10.1186/s40345-021-00237-1
Taylor RH, Ulrichsen A, Young AH, Strawbridge R. Affective lability as a prospective predictor of subsequent bipolar disorder diagnosis: a systematic review. Int J Bipolar Disord. 2021 Nov 01;9(1):33. doi: 10.1186/s40345-021-00237-1. PMID: 34719775; PMCID: PMC8558129.
Copy Download .nbib Format: NLM
Modulation of Small RNA Signatures in Schwann-Cell-Derived Extracellular Vesicles by the p75 Neurotrophin Receptor and Sortilin.

Biomedicines

Gonçalves NP, Yan Y, Ulrichsen M, Venø MT, Poulsen ET, Enghild JJ, Kjems J, Vægter CB.
PMID: 33114403
Biomedicines. 2020 Oct 24;8(11). doi: 10.3390/biomedicines8110450.

Schwann cells (SCs) are the main glial cells of the peripheral nervous system (PNS) and are known to be involved in various pathophysiological processes, such as diabetic neuropathy and nerve regeneration, through neurotrophin signaling. Such glial trophic support to...

Cite
Gonçalves NP, Yan Y, Ulrichsen M, et al. Modulation of Small RNA Signatures in Schwann-Cell-Derived Extracellular Vesicles by the p75 Neurotrophin Receptor and Sortilin. Biomedicines. 2020;8(11)doi: 10.3390/biomedicines8110450.
Gonçalves, N. P., Yan, Y., Ulrichsen, M., Venø, M. T., Poulsen, E. T., Enghild, J. J., Kjems, J., & Vægter, C. B. (2020). Modulation of Small RNA Signatures in Schwann-Cell-Derived Extracellular Vesicles by the p75 Neurotrophin Receptor and Sortilin. Biomedicines, 8(11), . https://doi.org/10.3390/biomedicines8110450
Gonçalves, Nádia P, et al. "Modulation of Small RNA Signatures in Schwann-Cell-Derived Extracellular Vesicles by the p75 Neurotrophin Receptor and Sortilin." Biomedicines vol. 8,11 (2020). doi: https://doi.org/10.3390/biomedicines8110450
Gonçalves NP, Yan Y, Ulrichsen M, Venø MT, Poulsen ET, Enghild JJ, Kjems J, Vægter CB. Modulation of Small RNA Signatures in Schwann-Cell-Derived Extracellular Vesicles by the p75 Neurotrophin Receptor and Sortilin. Biomedicines. 2020 Oct 24;8(11). doi: 10.3390/biomedicines8110450. PMID: 33114403; PMCID: PMC7694014.
Copy Download .nbib Format: NLM
Peripheral Nerve Regeneration Is Independent From Schwann Cell p75.

Frontiers in cellular neuroscience

Gonçalves NP, Mohseni S, El Soury M, Ulrichsen M, Richner M, Xiao J, Wood RJ, Andersen OM, Coulson EJ, Raimondo S, Murray SS, Vægter CB.
PMID: 31191256
Front Cell Neurosci. 2019 May 29;13:235. doi: 10.3389/fncel.2019.00235. eCollection 2019.

Schwann cell reprogramming and differentiation are crucial prerequisites for neuronal regeneration and re-myelination to occur following injury to peripheral nerves. The neurotrophin receptor p75

Cite
Gonçalves NP, Mohseni S, El Soury M, et al. Peripheral Nerve Regeneration Is Independent From Schwann Cell p75. Front Cell Neurosci. 2019;13:235doi: 10.3389/fncel.2019.00235.
Gonçalves, N. P., Mohseni, S., El Soury, M., Ulrichsen, M., Richner, M., Xiao, J., Wood, R. J., Andersen, O. M., Coulson, E. J., Raimondo, S., Murray, S. S., & Vægter, C. B. (2019). Peripheral Nerve Regeneration Is Independent From Schwann Cell p75. Frontiers in cellular neuroscience, 13235. https://doi.org/10.3389/fncel.2019.00235
Gonçalves, Nádia P, et al. "Peripheral Nerve Regeneration Is Independent From Schwann Cell p75." Frontiers in cellular neuroscience vol. 13 (2019): 235. doi: https://doi.org/10.3389/fncel.2019.00235
Gonçalves NP, Mohseni S, El Soury M, Ulrichsen M, Richner M, Xiao J, Wood RJ, Andersen OM, Coulson EJ, Raimondo S, Murray SS, Vægter CB. Peripheral Nerve Regeneration Is Independent From Schwann Cell p75. Front Cell Neurosci. 2019 May 29;13:235. doi: 10.3389/fncel.2019.00235. eCollection 2019. PMID: 31191256; PMCID: PMC6548843.
Copy Download .nbib Format: NLM
Obesity in young men, and individual and combined risks of type 2 diabetes, cardiovascular morbidity and death before 55 years of age: a Danish 33-year follow-up study.

BMJ open

Schmidt M, Johannesdottir SA, Lemeshow S, Lash TL, Ulrichsen SP, Bøtker HE, Sørensen HT.
PMID: 23628994
BMJ Open. 2013 Apr 29;3(4). doi: 10.1136/bmjopen-2013-002698. Print 2013.

OBJECTIVES: To examine the association between body mass index (BMI) in young adulthood and cardiovascular risks, including venous thromboembolism, before 55 years of age.DESIGN: Cohort study using population-based medical databases.SETTING: Outcomes registered from all hospitals in Denmark from 1977...

Cite
Schmidt M, Johannesdottir SA, Lemeshow S, et al. Obesity in young men, and individual and combined risks of type 2 diabetes, cardiovascular morbidity and death before 55 years of age: a Danish 33-year follow-up study. BMJ Open. 2013;3(4)doi: 10.1136/bmjopen-2013-002698.
Schmidt, M., Johannesdottir, S. A., Lemeshow, S., Lash, T. L., Ulrichsen, S. P., Bøtker, H. E., & Sørensen, H. T. (2013). Obesity in young men, and individual and combined risks of type 2 diabetes, cardiovascular morbidity and death before 55 years of age: a Danish 33-year follow-up study. BMJ open, 3(4), . https://doi.org/10.1136/bmjopen-2013-002698
Schmidt, Morten, et al. "Obesity in young men, and individual and combined risks of type 2 diabetes, cardiovascular morbidity and death before 55 years of age: a Danish 33-year follow-up study." BMJ open vol. 3,4 (2013). doi: https://doi.org/10.1136/bmjopen-2013-002698
Schmidt M, Johannesdottir SA, Lemeshow S, Lash TL, Ulrichsen SP, Bøtker HE, Sørensen HT. Obesity in young men, and individual and combined risks of type 2 diabetes, cardiovascular morbidity and death before 55 years of age: a Danish 33-year follow-up study. BMJ Open. 2013 Apr 29;3(4). doi: 10.1136/bmjopen-2013-002698. Print 2013. PMID: 23628994; PMCID: PMC3641453.
Copy Download .nbib Format: NLM
Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature.

Clinical case reports

Thomson N, Ulrickson M.
PMID: 27525082
Clin Case Rep. 2016 Jul 06;4(8):773-6. doi: 10.1002/ccr3.628. eCollection 2016 Aug.

Atypical hemolytic uremic syndrome (aHUS) patients treated with eculizumab may require higher doses to achieve and maintain optimal clinical response. Further studies are warranted to elucidate optimal dosing regimens of eculizumab in aHUS patients, and whether dosing regimens can...

Cite
Thomson N, Ulrickson M. Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature. Clin Case Rep. 2016;4(8):773-6doi: 10.1002/ccr3.628.
Thomson, N., & Ulrickson, M. (2016). Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature. Clinical case reports, 4(8), 773-6. https://doi.org/10.1002/ccr3.628
Thomson, Nick, and Ulrickson, Matthew. "Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature." Clinical case reports vol. 4,8 (2016): 773-6. doi: https://doi.org/10.1002/ccr3.628
Thomson N, Ulrickson M. Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature. Clin Case Rep. 2016 Jul 06;4(8):773-6. doi: 10.1002/ccr3.628. eCollection 2016 Aug. PMID: 27525082; PMCID: PMC4974426.
Copy Download .nbib Format: NLM
The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: Collection of baseline data from the first 580 patients.

Clinical epidemiology

Thomsen RW, Nielsen JS, Ulrichsen SP, Pedersen L, Hansen AM, Nilsson T.
PMID: 23071401
Clin Epidemiol. 2012;4:43-8. doi: 10.2147/CLEP.S30083. Epub 2012 Sep 21.

This paper provides an overview of the baseline data collected in the nationwide Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project. The paper presents descriptive data from the first 580 patients enrolled in the DD2. The...

Cite
Thomsen RW, Nielsen JS, Ulrichsen SP, et al. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: Collection of baseline data from the first 580 patients. Clin Epidemiol. 2012;4:43-8doi: 10.2147/CLEP.S30083.
Thomsen, R. W., Nielsen, J. S., Ulrichsen, S. P., Pedersen, L., Hansen, A. M., & Nilsson, T. (2012). The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: Collection of baseline data from the first 580 patients. Clinical epidemiology, 443-8. https://doi.org/10.2147/CLEP.S30083
Thomsen, Reimar Wernich, et al. "The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: Collection of baseline data from the first 580 patients." Clinical epidemiology vol. 4 (2012): 43-8. doi: https://doi.org/10.2147/CLEP.S30083
Thomsen RW, Nielsen JS, Ulrichsen SP, Pedersen L, Hansen AM, Nilsson T. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) study: Collection of baseline data from the first 580 patients. Clin Epidemiol. 2012;4:43-8. doi: 10.2147/CLEP.S30083. Epub 2012 Sep 21. PMID: 23071401; PMCID: PMC3470453.
Copy Download .nbib Format: NLM
Cardiometabolic risk factors associated with brain age and accelerate brain ageing.

Human brain mapping

Beck D, de Lange AG, Pedersen ML, Alnaes D, Maximov II, Voldsbekk I, Richard G, Sanders AM, Ulrichsen KM, Dørum ES, Kolskår KK, Høgestøl EA, Steen NE, Djurovic S, Andreassen OA, Nordvik JE, Kaufmann T, Westlye LT.
PMID: 34626047
Hum Brain Mapp. 2022 Feb 01;43(2):700-720. doi: 10.1002/hbm.25680. Epub 2021 Oct 09.

The structure and integrity of the ageing brain is interchangeably linked to physical health, and cardiometabolic risk factors (CMRs) are associated with dementia and other brain disorders. In this mixed cross-sectional and longitudinal study (interval mean = 19.7 months),...

Cite
Beck D, de Lange AG, Pedersen ML, et al. Cardiometabolic risk factors associated with brain age and accelerate brain ageing. Hum Brain Mapp. 2021;43(2):700-720doi: 10.1002/hbm.25680.
Beck, D., de Lange, A. G., Pedersen, M. L., Alnaes, D., Maximov, I. I., Voldsbekk, I., Richard, G., Sanders, A. M., Ulrichsen, K. M., Dørum, E. S., Kolskår, K. K., Høgestøl, E. A., Steen, N. E., Djurovic, S., Andreassen, O. A., Nordvik, J. E., Kaufmann, T., & Westlye, L. T. (2022). Cardiometabolic risk factors associated with brain age and accelerate brain ageing. Human brain mapping, 43(2), 700-720. https://doi.org/10.1002/hbm.25680
Beck, Dani, et al. "Cardiometabolic risk factors associated with brain age and accelerate brain ageing." Human brain mapping vol. 43,2 (2022): 700-720. doi: https://doi.org/10.1002/hbm.25680
Beck D, de Lange AG, Pedersen ML, Alnaes D, Maximov II, Voldsbekk I, Richard G, Sanders AM, Ulrichsen KM, Dørum ES, Kolskår KK, Høgestøl EA, Steen NE, Djurovic S, Andreassen OA, Nordvik JE, Kaufmann T, Westlye LT. Cardiometabolic risk factors associated with brain age and accelerate brain ageing. Hum Brain Mapp. 2022 Feb 01;43(2):700-720. doi: 10.1002/hbm.25680. Epub 2021 Oct 09. PMID: 34626047; PMCID: PMC8720200.
Copy Download .nbib Format: NLM
Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study.

Evidence-based mental health

Hálfdánarson Ó, Cohen JM, Karlstad Ø, Cesta CE, Bjørk MH, Håberg SE, Einarsdóttir K, Furu K, Gissler M, Hjellvik V, Kieler H, Leinonen MK, Nørgaard M, Öztürk Essen B, Ulrichsen SP, Reutfors J, Zoega H.
PMID: 34810174
Evid Based Ment Health. 2021 Nov 22; doi: 10.1136/ebmental-2021-300311. Epub 2021 Nov 22.

BACKGROUND: Antipsychotics are increasingly used among women of childbearing age and during pregnancy.OBJECTIVE: To determine whether children exposed to antipsychotics FINDINGS: Among 4 324 086 singleton births, 15 466 (0.4%) were exposed to antipsychotics DISCUSSION: Our findings suggest little...

Cite
Hálfdánarson Ó, Cohen JM, Karlstad Ø, et al. Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study. Evid Based Ment Health. 2021;doi: 10.1136/ebmental-2021-300311.
Hálfdánarson, �. �., Cohen, J. M., Karlstad, �. �., Cesta, C. E., Bjørk, M. H., Håberg, S. E., Einarsdóttir, K., Furu, K., Gissler, M., Hjellvik, V., Kieler, H., Leinonen, M. K., Nørgaard, M., Öztürk Essen, B., Ulrichsen, S. P., Reutfors, J., & Zoega, H. (2021). Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study. Evidence-based mental health, . https://doi.org/10.1136/ebmental-2021-300311
Hálfdánarson, Óskar, et al. "Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study." Evidence-based mental health vol. (2021). doi: https://doi.org/10.1136/ebmental-2021-300311
Hálfdánarson Ó, Cohen JM, Karlstad Ø, Cesta CE, Bjørk MH, Håberg SE, Einarsdóttir K, Furu K, Gissler M, Hjellvik V, Kieler H, Leinonen MK, Nørgaard M, Öztürk Essen B, Ulrichsen SP, Reutfors J, Zoega H. Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: a Nordic cohort study. Evid Based Ment Health. 2021 Nov 22; doi: 10.1136/ebmental-2021-300311. Epub 2021 Nov 22. PMID: 34810174.
Copy Download .nbib Format: NLM
Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings.

Advances in hematology

Ulrickson M, Press OW, Casper C.
PMID: 22548067
Adv Hematol. 2012;2012:932658. doi: 10.1155/2012/932658. Epub 2012 Mar 26.

Lymphoma was a common complication of HIV infection in the pre-antiretroviral era, and the incidence of HIV-associated lymphoma has dropped dramatically since the introduction of combination antiretroviral therapy (cART) in resource-rich regions. Conversely, lymphoma is an increasingly common complication...

Cite
Ulrickson M, Press OW, Casper C. Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings. Adv Hematol. 2012;2012:932658doi: 10.1155/2012/932658.
Ulrickson, M., Press, O. W., & Casper, C. (2012). Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings. Advances in hematology, 2012932658. https://doi.org/10.1155/2012/932658
Ulrickson, Matthew, et al. "Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings." Advances in hematology vol. 2012 (2012): 932658. doi: https://doi.org/10.1155/2012/932658
Ulrickson M, Press OW, Casper C. Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings. Adv Hematol. 2012;2012:932658. doi: 10.1155/2012/932658. Epub 2012 Mar 26. PMID: 22548067; PMCID: PMC3324149.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 30 entries